Results 171 to 180 of about 36,119 (263)

Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female – a case report and literature review [PDF]

, 2017
Samvel Bardakhchyan, Leo Kager, Samvel Danielyan, Armen Avagyan, Nerses Karamyan, Hovhannes Vardevanyan, Sergey Mkhitaryan, Ruzanna Papyan, Davit Zohrabyan, Liana Safaryan, Lilit Sargsyan, Lilit Harutyunyan, Lusine Hakobyan, Samvel Iskanyan, Gevorg Tamamyan   +14 more
openalex   +1 more source

Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma

, 2022
Hirofumi Makino, Masakazu Notsu, Itsuko Asayama, Hazuki Otani, Miwa Morita, Masahiro Yamamoto, Mika Yamauchi, Mika Nakao, Hitomi Miyake, Asuka Araki, Shinya Uchino, Keizo Kanasaki   +11 more
openalex   +2 more sources

Denosumab combined with curettage after surgical dislocation of the hip in the treatment of giant cell tumors of bone in the femoral head and neck region: a single-center retrospective study. [PDF]

BMC Musculoskelet Disord
Li J, Cai D, Yang Z, Zhang J, Lv Q, Jin W, Zhao L, Hong S.   +7 more
europepmc   +1 more source

Perils and Promises of Therapeutic Approaches for the Stem Cell Disease Fibrous Dysplasia [PDF]

, 2019
Saggio, Isabella
core   +1 more source

Effectiveness and safety of romosozumab followed by 2 years of sequential therapy with denosumab in a real-world setting

Kazuaki Mineta, Toshihiko Nishisho, Masahiko Okada, Mitsuhiro Kamada, Koichi Sairyo   +4 more
openalex   +1 more source

An Adrenal Crisis After Denosumab Use in a Patient With Addison's Disease: A Case Report. [PDF]

Cureus
Caglar H, Hira S, Caglar SO.
europepmc   +1 more source

265Discontinuing Denosumab: Safety & Experience from a Specialist Bone Health and Osteoporosis Clinic [PDF]

, 2018
Máire Rafferty, Rachel Mulpeter, Niamh Maher, Georgina Steen, Nessa Fallon, Miriam Casey, James Bernard Walsh, Kevin McCarroll, Rosaleen Lannon   +8 more
openalex   +1 more source

Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling. [PDF]

Nat Commun
Hu Y, Chen W, Lan S, Ming C, Xu D, Li H, Xu H, Shi D, Liu W, Dai Z, Wang J, He Z, Xu W, Shao Z, Liu Y, Tian H, Tong W.   +16 more
europepmc   +1 more source

Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis [PDF]

Xin Jin, Cai Huang, Yan Zhang, Ying Dong, Qi Xiong, Di Wang, Ziyi He, Lin Shen, Chen Ma, Zixian Wang, Bo Shuai   +10 more
openalex   +1 more source

Biochemical Markers of Bone Turnover as Predictors of Bone Mineral Density Response to Denosumab [PDF]

, 2017
Díaz Curiel M
openalex   +1 more source